Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address sulli025@mc.duke.edu

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Overview
Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971

Publications

Sullivan, KM, McSweeney, PA, and Nash, RA. "Cyclophosphamide in scleroderma lung disease." The New England Journal of Medicine 355, no. 11 (September 2006): 1173-1174. (Letter)

PMID
16977701
Full Text

Nash, RA, McSweeney, PA, Crofford, LJ, McDonagh, KT, Sullivan, KM, Maureen, M, Nelson, JL, Gooley, T, Holmberg, L, Shulman, H, Wener, M, McLaughlin, B, Henstorf, G, Molitor, J, Seibold, JR, and Furst, DE. "5-year follow-up of high-dose immunosuppressive therapy (HDIT) for systemic sclerosis (SSc)." September 2006.

Scholars@Duke

Nash, RA, McSweeney, PA, Nelson, JL, Wener, M, Georges, GE, Langston, AA, Shulman, H, Sullivan, KM, Lee, J, Henstorf, G, Storb, R, and Furst, DE. "Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis." Arthritis and Rheumatism 54, no. 6 (June 2006): 1982-1986.

PMID
16732546
Full Text

Horwitz, ME, and Sullivan, KM. "Chronic graft-versus-host disease." Blood Rev 20, no. 1 (January 2006): 15-27. (Review)

PMID
16426941
Full Text

Storek, J, Nash, RA, McSweeney, PA, Furst, DE, and Sullivan, KM. "Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis." Clinical Immunology 121, no. 1 (2006): 118-119.

PMID
16844418
Full Text

Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Sullivan, KM, Horwitz, M, Chute, J, Gong, JZ, Lagoo, AS, Niedzwiecki, D, Lu, CX, Marshall, D, Dowell, JM, and Chao, NJ. "Partially HLA matched, non-myeloablative allogeneic transplantation." 47th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA. December 10, 2005 - December 13, 2005.: AMER SOC HEMATOLOGY, November 16, 2005.

Scholars@Duke

Rizzieri, DA, Koh, LP, Long, GD, Gasparetto, C, Gong, JZ, Lagoo, AS, Niedzwiecki, D, Sullivan, KM, Chute, J, Horwitz, M, Ashley, M, and Chao, NJ. "Outcome and immune reconstitution following T cell depleted nonmyeloablative allogeneic transplantation using matched donors." November 16, 2005.

Scholars@Duke

Griffith, LM, Pavletic, SZ, Tyndall, A, Bredeson, CN, Bowen, JD, Childs, RW, Gratwohl, A, Laar, JMV, Mayes, MD, Martin, R, McSweeney, PA, Muraro, PA, Openshaw, H, Saccardi, R, Sandmaier, BM, Forman, SJ, Nash, RA, Antin, JH, Bishop, MR, Bredeson, CN, Forman, SJ, Giralt, S, Gratwohl, A, Gress, R, Hosing, C, Petersdorf, EW, Shizuru, JA, Sullivan, K, Tisdale, JF, Bowen, JD, Chen, J, Lassmann, H, Narayanan, S, Bocelli-Tyndall, C, Clements, PJ, Furst, DE, Illei, GG, McNamara, JD, and Mittleman, BB et al. "Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: Position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005." Biology of Blood and Marrow Transplantation 11, no. 11 (2005): 862-870.

PMID
16275589
Full Text

Storek, J, Zhao, Z, Lin, E, Berger, T, McSweeney, PA, Nash, RA, Akatsuka, Y, Metcalf, MD, Lu, H, Kalina, T, Reindl, M, Storb, R, Hansen, JA, Sullivan, KM, Kraft, GH, Furst, DE, and Maloney, DG. "Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)." Clinical Immunology (Orlando, Fla.) 113, no. 3 (December 2004): 285-298.

PMID
15507394
Full Text

Walters, MC, Patience, M, Edwards, S, Robertson, S, McMurray, M, Donfield, S, and Sullivan, KM. "Hematopoietic cell transplantation for sickle cell disease: Updated results of the multicenter trial." November 16, 2004.

Scholars@Duke

Pages